Breast Cancer Coverage from Every Angle

ABC Breast Cancer Trials of Adjuvant Taxane With or Without Anthracycline in HER2-Negative Disease

In patients with high-risk HER2-negative breast cancer, taxane plus doxorubicin/cyclophosphamide (TaxAC) regimens improved invasive disease–free survival compared with docetaxel/cyclophosphamide (TC6) regimens. This result is based on an efficacy analysis of three adjuvant Anthracyclines in Early Breast Cancer (ABC) trials: U.S. Oncology Research (USOR) 06-090, National Surgical Adjuvant Breast and Bowel Project (NSABP) B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). These findings were reported in the Journal of Clinical Oncology by Blum and colleagues.

In these trials, with a median follow-up of 3.3 years, 2,125 patients randomly received TC6 regimens, and TaxAC regimens were randomly given to 2,117 patients. A total of 334 invasive disease–free survival events were reported, and the hazard ratio for TC6 vs TaxAC was 1.202 (95% confidence interval: 0.97–1.49), which signaled early reporting for futility. Furthermore, the 4-year invasive disease–free survival for those receiving TC6 regimens was 88.2%, vs 90.7% for those receiving TaxAC regimens (P=.04).

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.